“Increased Risk of Serious Bleeding with Concomitant Use of Selective Serotonin Reuptake Inhibitors and Antithrombotics: A Pharmacovigilance Study”

https://pubmed.ncbi.nlm.nih.gov/38112734

This pharmacovigilance study suggests an increased risk of serious bleeding when selective serotonin reuptake inhibitors are associated with antithrombotics, including direct oral anticoagulants, vitamin K antagonists, platelet aggregation inhibitors, and heparins.